Cardiol Therapeutics Inc. filings document the formal disclosures of a Canadian life sciences issuer listed on Nasdaq and the TSX. Recent Form 6-K reports furnish press releases and exhibits covering CardiolRx clinical programs, including MAVERIC in recurrent pericarditis and ARCHER in acute myocarditis, as well as CRD-38 development, patent updates, and operating results summarized with audited financial statements and management discussion.
The filing record also documents governance and capital-structure matters, including annual general meeting notices, Class A common share voting mechanics, bought deal private placement terms, underwriting agreements, and warrant indenture provisions. These filings describe the company’s securities, financing arrangements, clinical-development disclosures, and foreign-issuer reporting framework.
Cardiol Therapeutics Inc. ownership update: MMCAP International Inc. SPC and MM Asset Management Inc. report shared beneficial ownership of 21,063,856 Class A Common Shares, representing 17.9% of the class as of March 31, 2026. The statement shows 15,352,317 directly owned shares plus 5,711,539 shares underlying warrants exercisable within 60 days. The filing attributes the Fund as the direct owner and the Adviser as investment manager; each Reporting Person disclaims ownership beyond the shares shown.
Cardiol Therapeutics Inc. filed a Form 6-K announcing it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York on May 19, 2026 at 1:30 p.m. EDT. A live webcast and 90-day replay will be available through the Investors section of the company’s website.
The filing also highlights Cardiol as a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead drug candidate, CardiolRx™, is being studied in recurrent pericarditis in the Phase II MAvERIC-Pilot study and the ongoing pivotal Phase III MAVERIC trial, and has U.S. FDA Orphan Drug Designation for pericarditis. Cardiol has also completed the Phase II ARCHER study in acute myocarditis and is developing CRD-38, a novel subcutaneous formulation aimed at inflammatory heart disease including heart failure.
Cardiol Therapeutics Inc. reported unaudited results for the three months ended March 31, 2026, showing a net loss of $10.8 million, compared with $8.3 million a year earlier, as research and development and share-based compensation expenses increased.
Cash and cash equivalents rose to $27.7 million from $21.4 million at December 31, 2025, primarily due to a $14.85 million unit financing completed in January 2026. Management expects this cash balance to fund planned operations and milestones into Q4 2027.
The company continued advancing its cardiovascular pipeline: the pivotal Phase III MAVERIC trial in recurrent pericarditis progressed beyond 50% then 75% enrollment, ARCHER Phase II myocarditis data were published in ESC Heart Failure, and IND-enabling work for subcutaneous candidate CRD-38 is underway with a budget of about $2 million.
Cardiol Therapeutics reports that Phase II results for its lead drug candidate CardiolRx™ in recurrent pericarditis have been accepted for publication in the Journal of the American Heart Association. The study found rapid and sustained reductions in pericarditis pain and inflammation in patients with a high disease burden.
The Phase II data also showed fewer pericarditis episodes per year and a favorable safety and tolerability profile, helping shape the pivotal Phase III MAVERIC trial, which has surpassed 75% enrollment. Cardiol positions CardiolRx™ as a differentiated, non-immunosuppressive therapy targeting inflammation-driven heart diseases, supported by U.S. FDA Orphan Drug Designation for pericarditis.
Cardiol Therapeutics Inc. reports continued progress in its pivotal Phase III MAVERIC trial of CardiolRx™ for recurrent pericarditis. U.S. patient enrollment has reached 75%, and the Company plans to activate up to seven additional U.S. clinical centers to support recruitment.
The MAVERIC trial is a randomized, double-blind, placebo-controlled study designed to enroll approximately 110 patients, with target recruitment anticipated by the end of Q2 2026 and potential extension into Q3. MAVERIC builds on Phase II data showing rapid and sustained reductions in pericarditis pain, inflammation, and recurrence rates.
Cardiol highlights the participation of premier cardiovascular research institutions and notes that CardiolRx™ has received U.S. FDA Orphan Drug Designation for pericarditis. Beyond MAVERIC, the Company references prior Phase II ARCHER data in acute myocarditis and ongoing development of its subcutaneous candidate CRD-38 for inflammatory heart disease.
Cardiol Therapeutics Inc. filed a report highlighting a live interview where its CEO will discuss key clinical programs. The session on X, hosted by Barchart, will cover the pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis, recent Phase II ARCHER results in acute myocarditis, and the Company’s next-generation heart failure candidate CRD-38. The filing also reiterates that Cardiol is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for serious heart diseases, with CardiolRx™ granted U.S. FDA Orphan Drug Designation for pericarditis.
Cardiol Therapeutics Inc. has scheduled its next annual general meeting of securityholders. The meeting will be held on June 24, 2026, with a record date of May 7, 2026 for both notice of meeting and voting rights, and for determining beneficial ownership.
The meeting will involve holders of Class A Common shares. The company will use notice-and-access procedures for both registered and beneficial holders and will pay for delivery of proxy materials to objecting beneficial owners. Odyssey Trust Company is acting as agent for Cardiol in this process.
Cardiol Therapeutics provides a year-end 2025 operations update highlighting major clinical, IP, and financing milestones. The Company advanced its pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis past 50% enrollment toward full enrollment expected in Q2 2026. Positive Phase II ARCHER data in 109 acute myocarditis patients showed CardiolRx™ significantly reduced left ventricular mass by 9.2g and improved multiple cardiac MRI endpoints, with full results published in ESC Heart Failure. Cardiol progressed its next-generation drug CRD-38 through IND-enabling work, received a U.S. patent allowance protecting CardiolRx™ and CRD-38 for major cardiac indications to October 2040, strengthened its Board, and raised an aggregate $31 million, extending cash runway into Q4 2027.
Cardiol Therapeutics Inc. files its Annual Report on Form 40-F, providing its audited financial statements, Management’s Discussion and Analysis, and related certifications for the fiscal year ended December 31, 2025. The filing states 100,257,009 shares outstanding as of the close of the period and confirms management concluded internal controls were effective as of December 31, 2025.
The report discloses audit fees of $403,570 for the fiscal year ended December 31, 2025 and notes the company is a Canadian foreign private issuer preparing financials under IFRS with amounts reported in Canadian dollars (exchange rate U.S.$1.00 = CDN$1.37 on December 31, 2025).
Cardiol Therapeutics Inc. filed a Form 6-K highlighting its upcoming presentation at the TD Cowen 46th Annual Health Care Conference in Boston. Company management will present on March 4, 2026, at 10:30 a.m. EST, with a live and replay webcast available in the Investors section of its website.
The filing also outlines Cardiol’s late-stage pipeline. Lead candidate CardiolRx™ targets inflammasome pathway activation in heart diseases such as recurrent pericarditis, acute myocarditis, and heart failure. Cardiol has completed Phase II studies in recurrent pericarditis and acute myocarditis and is conducting a pivotal Phase III trial in recurrent pericarditis, which has U.S. FDA Orphan Drug Designation.
Cardiol is additionally developing CRD-38, a novel subcutaneous formulation for inflammatory heart disease, including heart failure, a major cause of death and hospitalization with U.S. healthcare costs noted as exceeding US$30 billion per year.